A carregar...
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis
IMPORTANCE: Checkpoint inhibitors have a unique mechanism of action that differs from chemotherapy or targeted therapies. The validity of objective response rate (ORR) as a surrogate for progression-free survival (PFS) and overall survival (OS) in checkpoint-inhibitor trials is uncertain. OBJECTIVE:...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885200/ https://ncbi.nlm.nih.gov/pubmed/29470579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5236 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|